When was Tris Pharma founded?

Tris Pharma was founded in 2000 and raised its 1st funding round 18 years after it was founded.

Where is Tris Pharma located?

Tris Pharma is headquartered in Monmouth Junction, United States. It is registered at Monmouth Junction, New Jersey.

Who is the current CEO of Tris Pharma?

Ketan Mehta of Tris Pharma. They have also founded 1 company.

How many employees does Tris Pharma have?

As of Aug 31, 2026, the latest employee count at Tris Pharma is 517.

Is Tris Pharma a funded company?

Tris Pharma is a funded company, having raised a total of $125M across 3 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Sep 21, 2018.

When was the latest funding round of Tris Pharma?

Tris Pharma's latest funding was a $***** Grant (prize money) round on Sep 05, 2023, with participation from 1 investor.

Where does Tris Pharma rank among its competitors?

Tris Pharma ranks 136th amongst 2871 active competitors, of which 972 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Tris Pharma?

Tris Pharma's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Tris Pharma - 2026 Company Profile, Team, Funding & Competitors

Tris Pharma is a series B company based in Monmouth Junction (United States), founded in 2000 by Ketan Mehta. It operates as an Innovating transformative treatments for ADHD, pain, and CNS disorders. Tris Pharma has raised $125M in funding. The company has 2871 active competitors, including 972 funded and 713 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Innovating transformative treatments for ADHD, pain, and CNS disorders. This biopharmaceutical company focuses on developing and commercializing innovative medicines addressing unmet patient needs in neuroscience and other therapeutic categories. They utilize proprietary science and technology to create differentiated therapeutic approaches, including novel mechanisms and investigational compounds. Their commitment extends to delivering high-quality, patient-friendly therapeutics with maximum benefit. They have a robust pipeline of investigational therapies targeting ADHD, pain, addiction, and other central nervous system diseases. They are dedicated to advancing the science of pain biology and improving the lives of patients through innovation and a culture of care.

Website: www.trispharma.com/
Email ID: *****@trispharma.com
Phone Number: +1 **********
Registered Address: Monmouth Junction, New Jersey

Key Metrics

Founded Year

2000

Location

Monmouth Junction, United States

Stage

Series B

Total Funding

$125M in 3 rounds

Latest Funding Round

Grant (prize money), Sep 05, 2023, $*****

Investors

Deerfield & 1 more

Ranked

136^th among 2871 active competitors

Employee Count

517 as on Aug 31, 2026

Investment & Acquisitions

NextWave Pharmaceuticals & 1 more

Similar Companies

Jazz Pharmaceuticals & 581 more

View Tris Pharma's full profile

Tris Pharma is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Tris Pharma, Inc. CIN: 10251512 , United States, Active	Nov 19, 2023	-	-	-
TRIS PHARMA, INC. CIN: 32059154339 , United States, Active	Dec 24, 2015	-	-	-
Tris Pharma, Inc CIN: 22-3747409 , United States, Active	Dec 31, 1999	-	441 (As on Dec 31, 2021)	-
TRIS PHARMA, INC. CIN: 223747409 , United States, Active	Dec 26, 999	-	556 (As on Dec 31, 2024)	-

Tris Pharma has raised a total funding of $125M over 3 rounds. Its first funding round was on Sep 21, 2018. Its latest funding round was a Grant (prize money) round on Sep 05, 2023 for $*****. 1 investor participated in its latest round. Tris Pharma has 2 institutional investors.

Here is the list of recent funding rounds of Tris Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 05, 2023	6450737	Grant (prize money)	3342703	2381650	5658896	1035859
Sep 21, 2018	1398539	Conventional Debt	1997253	6882186	5515434	Deerfield
Sep 21, 2018	3852113	Series B	2783122	4955529	1450714	Deerfield

Access funding benchmarks and valuations. Sign up today!

View details of Tris Pharma's funding rounds and investors

The founders of Tris Pharma is Ketan Mehta. Ketan Mehta is the CEO of Tris Pharma.

Here are the details of Tris Pharma's key team members:

Ketan Mehta: Founder & CEO of Tris Pharma.

View details of Tris Pharma's Founder profiles and Board Members

Tris Pharma's employee count trend

Tris Pharma has 517 employees as of Aug 26. Here is Tris Pharma's employee count trend over the years:

Uncover Tris Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tris Pharma include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Tris Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
136th	Tris Pharma 2000, Monmouth Junction (United States), Series B	Innovating transformative treatments for ADHD, pain, and CNS disorders	$125M	Deerfield, NIH	61/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Tris Pharma's competitors? Click here to see the top ones

Tris Pharma has acquired 2 companies including NextWave Pharmaceuticals and NextWave Pharmaceuticals. Tris Pharma has not made any investments as of now.

Here is the latest report on Tris Pharma's sector: